KD019

DRUG2 trials

Sponsors

Kadmon Corporation, LLC, NYU Langone Health

Conditions

Carcinoma, Non-Small-Cell LungEsophageal CancerStomach Cancer

Phase 1

KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer

WithdrawnNCT02205463

NYU Langone HealthEsophageal Cancer, Stomach Cancer

Start: 2014-12-31End: 2017-07-31Updated: 2014-08-01

Phase 3

KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy

TerminatedNCT01487174

Kadmon Corporation, LLCCarcinoma, Non-Small-Cell Lung

Start: 2011-12-14End: 2013-07-25Updated: 2022-05-13